ICH Q12 establishes a framework for technical and regulatory considerations for pharmaceutical product lifecycle management, now being implemented across the US, EU, Japan, and increasingly emerging markets.
The guideline introduces Established Conditions (ECs) and Post-Approval Change Management Protocols (PACMPs), enabling companies to agree upfront with regulators on how to manage future changes.
Implementation Challenges
Organizations report challenges in legacy product retrospective analysis, particularly in defining appropriate ECs for products approved before Q12 existed.
평가 남기기